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Abstract
Intratumoral heterogeneity including genetic and non-
genetic mechanisms refers to biological differences 
amongst malignant cells originated within the same 
tumor. Both, cell differentiation hierarchy and stochas-
ticity in gene expression and signaling pathways may 
result in phenotypic differences of cancer cells. Since a 
tumor consists of cancer cell clones that display distinct 
behaviours, changes in clonal proliferative behavior 
may also contribute to the phenotypic variability of tu-
mor cells. There is a need to reveal molecular actions 
driving chemotherapeutic resistance in colon cancer 
cells. In general, it is widely hypothesized that therape-
utic resistance in colorectal cancer is a consequence of 
the preferential survival of cancer stem cells. However, 
recent data regarding colorectal cancer suggest that re-
sistance to anticancer therapy and post-therapeutic tu-
mor reappearence could be related to variations of clo-
nal dynamics. Understanding the interaction of genetic 
and nongenetic determinants influencing the functional 
diversity and therapy response of tumors should be a 
future direction for cancer research.
© 2014 Baishideng Publishing Group Co., Limited. All rights 
reserved.
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Core tip: Beyond genetic diversity, a complex level of 
nongenetic mechanisms exists and drives the intratu-
moral inherent functional heterogeneity of tumor cells. 
Recent data suggest that changes in clonal dynamics of 
colorectal cancer cells can lead to drug resistance and 
tumor reappearance. 
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COMMENTARY ON HOT TOPICS
Cancer is a major worldwide health problem. It exists and 
grows due to uncontrolled proliferation of  aberrant cells 
that are characterized by several different morphologi-
cal and pathophysiological properties. This intratumoral 
cellular diversity remains a major challenge in our un-
derstanding both, the cancerous process and therapeutic 
resistance. Cellular heterogeneity can be resulted due to 
genetic and nongenetic mechanisms. However, the degree 
of  interplay between these processes and their relative 
involvement in cancer propagation needs to be clarified. 
Intratumoral heterogeneity, in part, arises through 
accumulated genetic changes that, within single tumors, 
result in several cellular subclones with significant bio-
logical differences[1-3]. On the basis of  genetic changes, 
cell differentiation hierarchies can also contribute to 
cancer cell diversity[4-6]. Similarly, resistance to antitumoral 
therapies can arise on the basis of  genetic mutations[7,8]. 
Nevertheless, the results of  Kreso et al[9] indicate that bio-
logical differences amongst colorectal cancer cells can be 
provoked by the involvement of  additional, nongenetic 
mechanisms. 
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INTRATUMORAL GENETIC 
HETEROGENEITY
Cancer is the final result of  successive genetic changes, 
disturbing regulatory processes and investing tumor cells 
with survival and growth advantages[10]. Genetic muta-
tions lead to the selection of  affected cells and their prog-
eny[11]. Since intratumoral genetic heterogeneity is gener-
ally accompanied by variation in malignant behaviors[12], 
clonal genetic diversity of  tumor cells has been correlated 
with poor prognosis[13]. In several types of  cancers[3,14], 
heterogeneity in sequence mutations has been identified 
by exome sequencing of  different regions of  primary 
and metastatic tumors. These findings are of  important 
clinical merit, given the current focus on using drugs that 
target specific mutant proteins and downstream signaling 
molecules.
INTRATUMORAL NONGENETIC 
HETEROGENEITY
Besides genetic changes, some nongenetic (e.g., epigenetic 
changes, posttranslational modifications, cell differentiati-
on hierarchy) factors may also influence cell-cell variabili-
ty within a tumor.
To explore functional equivalence of  cancer cells 
within single genetic clones Kreso et al[9] combined deoxy-
ribonucleic acid (DNA) copy number alteration (CNA) 
profiling, sequencing, and lentiviral lineage tracking, fol-
lowed the repopulation dynamics of  150 single lentivirus-
marked lineages from 10 human colorectal cancers over 
multiple serial transplantations in mouse xenografts.  
DNA CNA profiling and mutational hotspot deep 
sequencing in 42 cancer-related genes indicated that a 
number of  tumor xenografts preserved the genomic pro-
file of  the primary tumor, whilst in some cases substan-
tial genetic differences were observed between the first 
transplant and the parental tumor, indicating the presence 
of  clonal selection during xenograft growth. However, 
the latter cancer cells also remained genetically stable in 
subsequent transplants. Furthermore, the results of  deep 
sequencing proved high concurrence amongst distinct 
single cell-derived clones. Based on these results, clonal 
stability of  colorectal cancer cells seems to be maintained 
through serial tumor transplantations. Consistent with 
earlier results[15], Kreso et al[9] showed that xenografting 
itself  did not select for a significantly different tumor cell 
population in relation of  multiple recipients at each stage 
of  serial transplantation. 
In spite of  the observed genetic homogeneity, the 
different, lentiviral marked cancer cell clones displayed 
different biological behaviours during serial transplanta-
tions. Persistent cell clones were present in all serial trans-
plants. Short-term clones did not persist, but exhausted 
before reaching the final passage. Transient clones were 
only detected in the first recipient, and were not detected 
in the second and subsequent recipients, therefore these 
clones lacked tumor-propagating ability. The presence of  
these clones suggests that there is a substantial functional 
diversity with respect to clonal longevity in the course of  
successive tumor transplantations. Additionally, cell clones 
with different dynamic behaviour were also observed. 
Resting clones were likely produced by cancer cells that 
were initially dormant (or slowly proliferating), but be-
came activated during later transplants, finally resulting in 
a measurable clone. Fluctuating clones consisted of  cells 
whose progeny appeared early, but they became undetect-
able in a subsequent transplantation, and only to reappear 
later. These clones displayed intermittently extensive pro-
liferative capacity. These results indicate that not all cancer 
cells having the potential for tumor propagation actually 
function and contribute to tumor growth at a given time. 
There are cells that can become activated at a later point 
of  tumor progression. The distinct clonal proliferative ki-
netics observed by Kreso et al[9] underscore the functional 
variability of  individual cells. Taking into account the ab-
sence of  changes in CNAs and single nucleotide variants 
with serial transplantations, these data provide evidence 
for functional heterogeneity amongst individual tumor-
propagating cells with a shared common genetic lineage. 
This phenotypic diversity results from the integration of  
both genetic and nongenetic influences. Nongenetic fac-
tors include stochasticity in gene expression, epigenetic 
regulation, and microenvironmental variability[16,17].
Based on the presence of  functionally heterogenous 
cancer cell clones, Kreso et al[9] further investigated the 
response of  these cells to oxaliplatin chemotherapy. 
Although the authors have found that chemotherapy 
reduced tumor mass, no apparent change in the absolute 
number of  marked clones, or the proportions of  clone 
types were observed. Tumor propagation capability of  
cancer cell clones was also found to be altered after ox-
aliplatin therapy. Despite eradication of  some lentiviral 
marked (mainly persistent cell) clones, resting or slowly 
proliferating cancer cells endured oxaliplatin therapy 
and reinitiated tumor growth in a slower manner. The 
results of  CNAs, single nucleotide variant and methyla-
tion pattern analyses indicated that oxaliplatin-treated 
cells genetically closely matched to the control recipients. 
These data suggest that therapeutic tolerance is not al-
ways caused by the acquisition of  new driver mutations. 
Behalf, alterations of  tumor propagation behaviour of  
individual cancer cells can act as a nongenetic deter-
minant of  tumor response to chemotherapy. Similarly, 
in human lung cancer a small subpopulation of  “anti-
epidermal growth factor receptor therapy-tolerant” cells 
were found[18]. This subpopulation of  cells demonstrated 
a highly reduced drug sensitivity and maintained viability 
via engagement of  insulin-like growth factor 1 receptor 
(IGF1R) signaling and an altered chromatin state that 
required histone demethylase activity. However, the drug-
tolerant subpopulation could be selectively ablated by 
treatment with IGF1R-inhibitors or chromatin-modifying 
agents, potentially yielding a therapeutic opportunity.
Although Kreso et al[9] did not discover mechanisms 
responsible for the variability in clonal behavior, their stu-
dy has several important values. It emphasizes the need 
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of  adequate understanding of  nongenetic processes that 
underlie phenotypic heterogeneity of  cancer cells. 
Upon technical procedures, a shift from classical 
assaying techniques using bulk cell populations (and 
masking single-cell level heterogeneity) to newly deve-
loped/advanced methods (e.g., combining laser pressure 
catapulting techniques with bisulfite-based arrays, next-
genome sequencing arrays or whole genome gene expres-
sion arrays) is expected. Moreover, their findings highlight 
on demand of  efforts to reveal molecular actions driving 
chemotherapeutic resistance in colorectal cancer cells. In 
general, it is widely hypothesized that therapeutic resistan-
ce in cancer is a consequence of  the preferential survival 
of  cancer stem cells. However, the results of  Kreso et al[9] 
suggest that cellular drug resistance and post-therapeu-
tic tumor reappearence could not only be related to the 
stem-cell characteristics, but also to variations of  clonal 
dynamics (Figure 1). 
Recent findings of  Kreso et al[9] reveal that, beyond 
genetic diversity, a complex level of  nongenetic mechan-
isms exists and drives the intratumoral inherent functi-
onal heterogeneity of  tumor cells. Thus, understanding 
the interaction of  genetic and nongenetic determinants 
influencing the functional diversity and therapy response 
for cancers should be a prominent future direction for 
cancer research. 
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Figure 1  Connection between clonal behaviour and cellular constitution of the tumor. Differences in clonal behavior result in changes of the cellular constitution 
of colorectal cancer during normal tumor growth and after chemotherapy as well. In the case of unperturbed tumor growth the proportion of the persistent cell clone 
increases, short-term cells fade away, while the number of resting cells remains unchanged. Transient cells may appear but later they also fade away. After oxaliplatin 
therapy the number of the highly proliferative (hence chemotherapy sensitive) persistent cells significantly decreases, while the drug resistant resting cell clone con-
tributes to tumor reappearance.
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